Craneware plc (CRW.L)
Powering administrative and financial software for US hospitals, Craneware operates quietly behind the scenes of American healthcare.
Is Craneware plc a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Impressive gross margin of over eighty-six percent highlighting software efficiency. Worth weighing: Modest overall revenue growth sits below five point seven percent. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Craneware plc actually fallen?
Over the last 2 years of daily prices, Craneware plc fell as much as −58% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Craneware cements its position as essential infrastructure for US hospitals.
Larger tech competitors crowd out niche healthcare software providers.
What does Craneware plc do?
Craneware provides software that helps US healthcare providers manage billing, pricing, and compliance so they stay financially healthy. It makes money through long-term software subscriptions, locking hospitals into its ecosystem. Keep a close eye on how quickly it converts its massive earnings growth into steady, everyday revenue increases.
On our factor screen it looks strongest on quality and growth, and weakest on momentum.
- ✓Pays a dividend - about 2.9% a year
- ✓Growing - revenue up about 6% over the year
- ✓Low debt - a sturdier balance sheet
- Impressive gross margin of over eighty-six percent highlighting software efficiency
- Strong recent earnings growth of nearly thirty-eight percent year-on-year
- Provides a reliable dividend yield of almost three percent
- Momentum screens low (3/100)
- Heavy reliance on the financial health and IT budgets of US hospitals
- Potential for delayed contract renewals in a complex regulatory market
- Currency fluctuations between British pounds and US dollars
What do Craneware plc's numbers mean?
Does Craneware plc pay a dividend?
Yes - Craneware plc currently pays a dividend of about 2.9% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
What do the numbers say about Craneware plc's dividend?
There's no rating here, and we don't judge whether the dividend will continue - that would be advice. Here are the figures income investors usually look at, and what each one means, so you can weigh it up yourself.
Figures are from the latest available data and can be distorted by one-off results. Past payments don't predict future ones, and a dividend can be cut at any time. This lays out the numbers to help you understand them - it is not a view on what will happen.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Craneware plc?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Craneware plc?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Impressive gross margin: The share of each £1 of sales left after the direct cost of making the product, before other running costs. Higher usually means more pricing power. of over eighty-six percent highlighting software efficiency
- Strong recent earnings growth of nearly thirty-eight percent year-on-year
- Provides a reliable dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone. of almost three percent
- Deeply embedded relationships with US healthcare providers
- Modest overall revenue growth: How fast the company's sales grew versus a year ago. sits below five point seven percent
- Return on equity: How much profit the company makes for each £1 shareholders have put in. Higher usually means a more efficient business. is relatively low at six point seven percent
- The share price has suffered a severe drop of over forty-eight percent in twelve months
- Heavy reliance on the financial health and IT budgets of US hospitals
- Potential for delayed contract renewals in a complex regulatory market
- Currency fluctuations between British pounds and US dollars
The write-up's own warning lights — if these start happening, the case above changes.
- A sudden acceleration or deceleration in multi-year hospital contracts
- A permanent shift in net profit margins away from historical norms
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.